Targeted Delivery of c(RGDfk)‐Modified Liposomes to Bone Marrow Through In Vivo Hitchhiking Neutrophils for Multiple Myeloma Therapy
Advanced Science · 2025-03 · 12 (12)
DOI: 10.1002/advs.202409895 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 16.12.2024. Verfasst von Huiwen Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, Hubei, 430022, China. Hauptthemen laut MEDLINE: Multiple Myeloma, Liposomes, Neutrophils, Bone Marrow. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Research Grant of Key Laboratory of Molecular Biological Targeted Therapies of the Ministry of Education.
Abstract (Originalsprache)
Multiple myeloma (MM) is a prevalent bone marrow disorder. The challenges in managing MM include selecting chemotherapy regimens that effectively modulate the myeloma microenvironment and delivering them to the bone marrow with high efficacy and minimal toxicity. Herein, a novel bone marrow targeting strategy using c(RGDfk) peptide‐modified liposomes loaded with chemotherapeutics is developed, which can specifically recognize and hitchhike neutrophils following systemic administration, capitalizing on their natural aging process to facilitate precise drug delivery to the bone marrow, thus minimizing off‐target effects. On the one hand, c(RGDfk)‐functionalized liposomes containing carfilzomib (CRLPs) successfully transformed macrophages from M2 phenotype to M1 phenotype, enhancing immunotherapeutic responses. On the other hand, c(RGDfk)‐functionalized liposomes encapsulating BMS‐202 (BRLPs), a small molecule checkpoint inhibitor, interrupted the PD‐1/PD‐L1 axis and promoted the infiltration of cytotoxic T cells. The co‐administration of CRLPs and BRLPs successfully delivered drugs to bone marrow, leading to significant modulation of the myeloma microenvironment, reduced tumor growth, and improved survival time of MM‐bearing mouse models. These findings introduced an alternative approach to modulating the myeloma microenvironment and underscored the efficacy of hitchhiking neutrophils for bone marrow drug delivery. This strategy show advantages over traditional drug delivery methods in terms of improved efficacy and lowered toxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, Hubei, 430022, China.
- Key lab of Molecular Biological Targeted Therapies of the Ministry of Education, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
- Department of Pathology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
- School of Pharmacy, Fudan University, Key Laboratory of Smart Drug Delivery, Ministry of Education, 826 Zhangheng Road, Shanghai, 201203, China.
ORCID-Profile: Zhiqing Pang
Förderung
- National Natural Science Foundation of China
- Research Grant of Key Laboratory of Molecular Biological Targeted Therapies of the Ministry of Education
Zitieren
APA
Liu, H., Zhang, B., Chen, H., Wang, H., Qin, X., Sun, C., Pang, Z., & Hu, Y. (2025). Targeted Delivery of c(RGDfk)‐Modified Liposomes to Bone Marrow Through In Vivo Hitchhiking Neutrophils for Multiple Myeloma Therapy. Advanced Science, 12(12). https://doi.org/10.1002/advs.202409895
Vancouver
Liu H, Zhang B, Chen H, Wang H, Qin X, Sun C, et al. Targeted Delivery of c(RGDfk)‐Modified Liposomes to Bone Marrow Through In Vivo Hitchhiking Neutrophils for Multiple Myeloma Therapy. Advanced Science. 2025;12(12). doi:10.1002/advs.202409895
BibTeX
@article{Liu2025,
author = {Liu, Huiwen and Zhang, Bo and Chen, Hongrui and Wang, Honglan and Qin, Xifeng and Sun, Chunyan and Pang, Zhiqing and Hu, Yu},
title = {Targeted Delivery of c(RGDfk)‐Modified Liposomes to Bone Marrow Through In Vivo Hitchhiking Neutrophils for Multiple Myeloma Therapy},
journal = {Advanced Science},
year = {2025},
volume = {12},
number = {12},
doi = {10.1002/advs.202409895}
}
EUVIMED